Novel Biomarkers for Personalized Cancer Immunotherapy

Cancer immunotherapy has emerged as a novel and effective treatment strategy for several types of cancer. Immune checkpoint inhibitors (ICIs) have recently demonstrated impressive clinical benefit in some advanced cancers. Nonetheless, in the majority of patients, the successful use of ICIs is limit...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2019-08, Vol.11 (9), p.1223
Main Authors: Shindo, Yoshitaro, Hazama, Shoichi, Tsunedomi, Ryouichi, Suzuki, Nobuaki, Nagano, Hiroaki
Format: Article
Language:English
Subjects:
Biomarkers
Cancer
Cancer immunotherapy
Immune checkpoint inhibitors
Immunotherapy
Lymphocytes
Mutation
Patients
Review
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer immunotherapy has emerged as a novel and effective treatment strategy for several types of cancer. Immune checkpoint inhibitors (ICIs) have recently demonstrated impressive clinical benefit in some advanced cancers. Nonetheless, in the majority of patients, the successful use of ICIs is limited by a low response rate, high treatment cost, and treatment-related toxicity. Therefore, it is necessary to identify predictive and prognostic biomarkers to select the patients who are most likely to benefit from, and respond well to, these therapies. In this review, we summarize the evidence for candidate biomarkers of response to cancer immunotherapy.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers11091223